首页> 外文OA文献 >Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration
【2h】

Development and characterization of a novel lipid nanocapsule formulation of Sn38 for oral administration

机译:开发和表征用于口服给药的新型sn38脂质纳米胶囊制剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this work was to encapsulate 7-Ethyl-10-hydroxy-camptothecin (Sn38) in lipid nanocapsules (LNCs) using phase inversion-based method in order to deliver Sn38 by oral route. LNCs were prepared by a low-energy emulsification method and were characterized for size, polydispersity index (PDI), surface charge, drug payload, in vitro drug release, and storage stability. Moreover, in view of an oral administration, in vitro stability in gastrointestinal fluid and permeability across Caco-2 cells were tested. Sn38-loaded LNCs with a mean particle size of 38+/-2nm were obtained. The particles displayed a narrow size distribution and a drug payload of 0.40+/-0.07mg/g of LNC dispersion. In vitro stability in simulated gastric and intestinal media was also observed. Finally, Sn38-loaded LNCs improved permeability of Sn38 across Caco-2 cells (5.69+/-0.87x10(6)cms(-1) at 6h vs 0.31+/-0.02x10(6)cms(-1)) and intracellular concentration compared with free Sn38. In conclusion, Sn38 nanocarriers have been developed and display a strong potential for oral administration.
机译:这项工作的目的是使用基于相转化的方法将7-乙基-10-羟基喜树碱(Sn38)封装在脂质纳米胶囊(LNC)中,以便通过口服途径递送Sn38。 LNC是通过低能乳化方法制备的,并具有尺寸,多分散指数(PDI),表面电荷,药物有效载荷,体外药物释放和储存稳定性的特征。此外,鉴于口服给药,测试了胃肠道液中的体外稳定性和跨Caco-2细胞的渗透性。获得了平均粒径为38 +/- 2nm的Sn38负载LNC。颗粒显示出窄的尺寸分布和0.40 +/- 0.07mg / g的LNC分散体的药物有效载荷。还观察到在模拟的胃和肠介质中的体外稳定性。最后,负载Sn38的LNC改善了Sn38跨Caco-2细胞的渗透性(在6h时分别为5.99 +/- 0.87x10(6)cms(-1)对0.31 +/- 0.02x10(6)cms(-1))和细胞内浓度与游离Sn38相比。总之,已经开发了Sn38纳米载体,并且显示出口服的强大潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号